Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PI3Kα inhibitor’s R&D prospects beyond breast cancer. The biotech on Tuesday shared Phase 2
Sanjiv Patel, Relay Therapeutics CEO May 19, 2026 07:13 AM EDT R&D Relay's PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study Ayisha Sharma News Reporter Relay Therapeutics’ first data readout for zovegalisib in a rare genetic disease beat Wall Street expectations, expanding the PIK3α inhibitor’s R&D prospects beyond breast cancer. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that